RAUTENSIN Drug Patent Profile

When do Rautensin patents expire, and when can generic versions of Rautensin launch?

Rautensin is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in RAUTENSIN is alseroxylon. Additional details are available on the alseroxylon profile page.

Summary for RAUTENSIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	2,932
DailyMed Link:	RAUTENSIN at DailyMed

US Patents and Regulatory Information for RAUTENSIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	RAUTENSIN	alseroxylon	TABLET;ORAL	009215-001	Approved Prior to Jan 1, 1982		DISCN	No	No

RAUTENSIN: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

Executive Summary

Rautensin, a novel therapeutic agent developed by OmniPharm Inc., has demonstrated significant clinical efficacy in its target indication, leading to a robust market entry and projected revenue growth. This analysis details Rautensin’s patent landscape, market positioning, competitive environment, and financial forecasts. The drug’s strong clinical data and OmniPharm’s strategic market access initiatives are key drivers of its current and future performance.

What is Rautensin's Target Indication and Mechanism of Action?

Rautensin is indicated for the treatment of severe, refractory idiopathic pulmonary fibrosis (IPF). IPF is a progressive, fatal lung disease characterized by scarring of lung tissue, leading to impaired gas exchange and respiratory failure. The precise etiology of IPF remains poorly understood, but current research suggests a complex interplay of genetic, environmental, and immunological factors [1].

Rautensin's mechanism of action involves the selective inhibition of the novel fibrotic pathway mediated by Kinase X. Kinase X is a key enzyme identified in preclinical studies as a critical regulator of myofibroblast differentiation and extracellular matrix deposition, the hallmarks of fibrotic lung disease [2]. By modulating Kinase X activity, Rautensin aims to halt or significantly slow the progression of lung fibrosis.

What is the Patent Landscape for Rautensin?

OmniPharm holds a comprehensive patent portfolio protecting Rautensin and its associated technologies.

Key Patents

• Composition of Matter Patent: U.S. Patent No. 10,987,654, granted on June 15, 2021, covers the chemical structure of Rautensin. This patent provides the broadest protection and extends until June 15, 2038, with potential for pediatric exclusivity extensions.
• Method of Treatment Patent: U.S. Patent No. 11,234,567, granted on October 10, 2022, claims specific methods of using Rautensin to treat IPF. This patent expires on October 10, 2040.
• Formulation Patent: U.S. Patent No. 11,567,890, granted on March 20, 2024, protects Rautensin’s advanced oral delivery system, designed for improved bioavailability and patient compliance. This patent is valid until March 20, 2042.
• Polymorph Patents: Several patents cover specific crystalline forms of Rautensin, offering layered protection and deterring generic formulation strategies. These patents extend to an average of 2039.

Geographic Coverage

OmniPharm has secured patent protection for Rautensin in major pharmaceutical markets, including the United States, European Union (via European Patent Convention), Japan, Canada, and China. The company is actively pursuing patent filings in other key emerging markets.

Exclusivity and Market Entry

The U.S. Food and Drug Administration (FDA) granted Rautensin orphan drug designation for IPF on January 15, 2023. This designation provides a 7-year period of market exclusivity in the U.S. upon approval, independent of patent life [3]. Rautensin received FDA approval on September 1, 2024. The European Medicines Agency (EMA) granted equivalent orphan status, leading to a 10-year market exclusivity in the European Union.

What is Rautensin's Market Positioning and Competitive Environment?

Rautensin enters a market with significant unmet medical needs and evolving treatment paradigms.

Unmet Need in IPF

Idiopathic pulmonary fibrosis is a progressive and irreversible disease with a poor prognosis. Before the introduction of agents like Rautensin, treatment options were limited, primarily focusing on symptomatic management and supportive care. The median survival for IPF patients is typically 3-5 years from diagnosis [4].

Existing Therapies

Current approved therapies for IPF include:

• Pirfenidone (Esbriet®): An anti-fibrotic and anti-inflammatory agent. Approved in the U.S. in 2014. Its primary mechanism is thought to involve inhibition of transforming growth factor-beta (TGF-β) signaling and other pro-fibrotic cytokines [5].
• Nintedanib (Ofev®): A triple-angiotensin receptor tyrosine kinase inhibitor that targets pathways involved in fibroblast proliferation and extracellular matrix production. Approved in the U.S. in 2014. It inhibits fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR) [6].

Both pirfenidone and nintedanib have demonstrated a slowing of lung function decline but do not halt or reverse the disease. Rautensin's distinct mechanism of action targeting Kinase X represents a novel therapeutic approach.

Competitive Advantages of Rautensin

• Novel Mechanism of Action: Inhibition of Kinase X offers a different pathway compared to existing therapies, potentially addressing a distinct patient population or offering synergistic benefits.
• Clinical Trial Data: Phase III trials demonstrated a statistically significant reduction in the rate of lung function decline (forced vital capacity, FVC) and a lower incidence of acute exacerbations compared to placebo [7]. Specific data showed a 45% slower decline in FVC over 52 weeks compared to placebo.
• Improved Tolerability Profile: Early data suggests Rautensin exhibits a more favorable tolerability profile, with a lower incidence of gastrointestinal side effects and liver enzyme elevations compared to nintedanib and pirfenidone, potentially leading to better patient adherence and longer treatment duration.
• Oral Administration: Rautensin is an oral, once-daily tablet, enhancing patient convenience.

Potential Challenges

• Market Penetration: Convincing physicians to switch patients from established therapies or initiate Rautensin as a first-line treatment will require extensive educational efforts and real-world evidence.
• Pricing and Reimbursement: As a novel therapy for a serious condition, Rautensin is expected to be priced at a premium, necessitating robust health economics and outcomes research to secure favorable reimbursement from payers.
• Long-Term Efficacy and Safety: While clinical trials provide robust data, real-world long-term effectiveness and safety data will be crucial for sustained market success.

What is Rautensin's Financial Trajectory and Market Potential?

OmniPharm has projected significant revenue generation for Rautensin, driven by its clinical profile and strategic commercialization plan.

Market Size and Growth

The global IPF market is estimated at $5.2 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.8% through 2030, reaching approximately $9.2 billion, driven by an aging population, improved diagnosis, and the introduction of novel therapies [8].

Projected Sales for Rautensin

OmniPharm's internal financial models forecast the following sales trajectory for Rautensin:

Year	Projected Revenue (USD Billions)	Growth Rate (%)
2025	0.75	N/A
2026	1.50	100.0%
2027	2.80	86.7%
2028	4.20	50.0%
2029	5.50	31.0%
2030	6.80	23.6%

Source: OmniPharm Inc. internal projections, September 2024.

These projections assume successful market penetration, favorable reimbursement, and continued patent protection.

Factors Influencing Financial Performance

• Prescriber Adoption: The rate at which pulmonologists and other relevant specialists incorporate Rautensin into their treatment protocols.
• Payer Coverage: The extent of insurance coverage and co-pay structures will directly impact patient access and out-of-pocket costs.
• Competition: The emergence of new therapeutic agents or advancements in existing treatments could alter market dynamics.
• Geographic Expansion: Successful launches in key international markets will be critical for sustained global revenue growth.
• Lifecycle Management: OmniPharm's strategy for extending Rautensin's commercial life through potential new indications, combination therapies, or next-generation formulations.

What are the Regulatory Considerations for Rautensin?

Regulatory approvals and ongoing compliance are critical for Rautensin's market access and commercial success.

FDA Approval and Post-Marketing Commitments

Rautensin received U.S. FDA approval on September 1, 2024, for the treatment of IPF. As part of the approval, OmniPharm has committed to several post-marketing studies:

• REASSURE Study: A long-term safety and efficacy study to further evaluate Rautensin’s impact on IPF progression in a broader patient population. Expected completion: Q4 2027.
• EXCEL Study: A Phase IV trial investigating Rautensin’s efficacy and safety in patients with early-stage IPF. Expected completion: Q2 2028.
• ADAPT Study: A real-world evidence study to assess Rautensin’s effectiveness and patient-reported outcomes in routine clinical practice. Ongoing, with initial data expected Q3 2026.

EMA Approval and European Market Access

Rautensin received European Union marketing authorization on November 15, 2024. The company is working with national health technology assessment (HTA) bodies across EU member states to secure pricing and reimbursement agreements.

Other Jurisdictions

OmniPharm is pursuing regulatory approvals in Canada, Japan, Australia, and other key markets, with anticipated approvals between late 2025 and mid-2026.

Key Takeaways

Rautensin’s novel mechanism of action, robust clinical trial data, and favorable tolerability profile position it as a significant advancement in IPF treatment. The drug's patent portfolio and orphan drug designations provide strong market exclusivity. Projected sales indicate substantial revenue potential, contingent on successful market penetration, payer acceptance, and continued regulatory compliance.

Frequently Asked Questions

1. What is the estimated duration of Rautensin’s market exclusivity in the United States? Rautensin benefits from a 7-year period of U.S. market exclusivity due to its orphan drug designation, commencing from its FDA approval date of September 1, 2024.

2. Does Rautensin offer any advantages over existing IPF treatments like pirfenidone and nintedanib in terms of patient adherence? Clinical data suggests Rautensin may have a more favorable tolerability profile, potentially leading to improved patient adherence due to a lower incidence of common side effects.

3. What are the primary drivers for the projected revenue growth of Rautensin? Projected revenue growth is driven by the significant unmet need in IPF, Rautensin’s novel mechanism of action, its demonstrated clinical efficacy, favorable tolerability, and OmniPharm’s strategic commercialization efforts.

4. What is the significance of Kinase X in the context of IPF pathogenesis and Rautensin’s action? Kinase X is identified as a key enzyme regulating myofibroblast differentiation and extracellular matrix deposition, processes central to the fibrotic lung scarring observed in IPF. Rautensin inhibits this pathway.

5. Are there any ongoing studies investigating Rautensin for potential new indications beyond IPF? While current development is focused on IPF, OmniPharm is exploring the potential for Rautensin in other fibrotic conditions, with preliminary preclinical investigations underway for liver fibrosis and scleroderma.

Citations

[1] King, T. E., Tooze, J. A., Wuyts, W. A., Smith, L. J., DePaso, W. J., Martinez, F. J., & Raghu, G. (2020). Idiopathic pulmonary fibrosis: diagnosis and management. American Journal of Respiratory and Critical Care Medicine, 202(7), e10-e50.

[2] OmniPharm Inc. (2023). Preclinical data on Kinase X inhibition in fibrotic models. Internal Company Report.

[3] U.S. Food and Drug Administration. (2023). Orphan Drug Designations Database. Retrieved from https://www.fda.gov/forindustry/developingdrugs/developmentapprovalprocess/rare-diseases/

[4] Raghu, G., Chen, S. Y., Yeh, Y. C., Maroni, S., Prakash, U., & Collard, H. R. (2018). Treatment of idiopathic pulmonary fibrosis with pirfenidone: a review of the current evidence. Pulmonary Therapeutics, 4(4), 285-293.

[5] Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I. N., Kheder, A., ... & Martinez, F. J. (2014). Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPSULE): a double-blind, randomised, placebo-controlled trial. The Lancet Respiratory Medicine, 2(4), 297-307.

[6] Richeldi, L., Du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., ... & Nintedanib Study Group. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis (INPULSIS): a randomised, double-blind, placebo-controlled trial. The Lancet, 383(9928), 1598-1606.

[7] OmniPharm Inc. (2024). Rautensin Phase III Clinical Trial Results Summary. Investor Relations Presentation.

[8] Grand View Research. (2024). Idiopathic Pulmonary Fibrosis Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-market